Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
Intervalo de año de publicación
1.
Am J Respir Cell Mol Biol ; 47(5): 589-96, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-22721832

RESUMEN

Recent studies suggest that airway smooth muscle remodeling is an early event in the course of asthma. Little is known of the effects of long-term antigen avoidance and inhaled corticosteroids on chronically established airway remodeling. We sought to measure the effects of inhaled corticosteroids and antigen avoidance on airway remodeling in the peripheral airways of horses with heaves, a naturally occurring asthma-like disease. Heaves-affected adult horses with ongoing airway inflammation and bronchoconstriction were treated with fluticasone propionate (with and without concurrent antigen avoidance) (n = 6) or with antigen avoidance alone (n = 5). Lung function and bronchoalveolar lavage were performed at multiple time points, and peripheral lung biopsies were collected before and after 6 and 12 months of treatment. Lung function improved more quickly with inhaled corticosteroids, but eventually normalized in both groups. Inflammation was better controlled with antigen avoidance. During the study period, corrected smooth muscle mass decreased from 12.1 ± 2.8 × 10(-3) and 11.3 ± 1.2 × 10(-3) to 8.3 ± 1.4 × 10(-3) and 7.9 ± 1.0 × 10(-3) in the antigen avoidance and fluticasone groups, respectively (P = 0.03). At 6 months, smooth muscle mass was significantly smaller compared with baseline only in the fluticasone-treated animals. The subepithelial collagen area was lower at 12 months than at baseline in both groups. During the study period, airway smooth muscle remodeling decreased by approximately 30% in both groups, although the decrease was faster in horses receiving inhaled corticosteroids. Inhaled corticosteroids may accelerate the reversal of smooth muscle remodeling, even if airway inflammation is better controlled with antigen avoidance.


Asunto(s)
Corticoesteroides/administración & dosificación , Androstadienos/administración & dosificación , Antígenos de Plantas/inmunología , Asma/veterinaria , Broncodilatadores/administración & dosificación , Enfermedades de los Caballos/tratamiento farmacológico , Músculo Liso/patología , Administración por Inhalación , Corticoesteroides/farmacología , Remodelación de las Vías Aéreas (Respiratorias)/efectos de los fármacos , Resistencia de las Vías Respiratorias , Androstadienos/farmacología , Animales , Asma/tratamiento farmacológico , Asma/inmunología , Asma/patología , Bronquiolos/inmunología , Bronquiolos/patología , Líquido del Lavado Bronquioalveolar , Broncodilatadores/farmacología , Proliferación Celular , Colágeno/metabolismo , Citocinas/metabolismo , Fluticasona , Enfermedades de los Caballos/inmunología , Enfermedades de los Caballos/patología , Caballos , Mediadores de Inflamación/metabolismo , Pulmón/efectos de los fármacos , Pulmón/patología , Pulmón/fisiopatología , Monocitos/metabolismo , Tamaño de los Órganos/efectos de los fármacos , Antígeno Nuclear de Célula en Proliferación/metabolismo , Pruebas de Función Respiratoria , Mucosa Respiratoria/metabolismo , Mucosa Respiratoria/patología , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA